Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT03401294

Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.

Led by University of Saskatchewan · Updated on 2025-05-09

32

Participants Needed

1

Research Sites

87 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and bevacizumab and to assess the association between an early FDG-PT/CT response and other clinical and pathological biomarkers and hepatic metastasectomy.

CONDITIONS

Official Title

Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged between 18 and 70 years with confirmed adenocarcinoma or poorly differentiated carcinoma of the colon or rectum
  • Unresectable liver-only metastases without disease outside the liver
  • WHO performance status of 0 to 1
  • No prior chemotherapy for advanced colorectal cancer
  • Adequate bone marrow, liver, and kidney function
Not Eligible

You will not qualify if you...

  • Currently pregnant or breastfeeding
  • Active second primary cancer except for skin squamous cell carcinoma or in situ cancer
  • Severe or uncontrolled medical conditions

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Allan Balir Cancer Center

Regina, Saskatchewan, Canada

Actively Recruiting

Loading map...

Research Team

S

Shahid Ahmed, MD, PhD

CONTACT

M

Michael Moser

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here